{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:11:46Z","timestamp":1768781506721,"version":"3.49.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T00:00:00Z","timestamp":1593216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T00:00:00Z","timestamp":1593216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Bladder Dysfunct Rep"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s11884-020-00592-2","type":"journal-article","created":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T05:13:54Z","timestamp":1593234834000},"page":"192-202","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Systemic Therapy for Bladder Pain Syndrome\/Interstitial Cystitis (BPS\/IC): Systematic Review of Published Trials in the Last 5 Years"],"prefix":"10.1007","volume":"15","author":[{"given":"Pedro","family":"Abreu-Mendes","sequence":"first","affiliation":[]},{"given":"Rui","family":"Pinto","sequence":"additional","affiliation":[]},{"given":"Paulo Dinis","family":"Oliveira","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2020,6,27]]},"reference":[{"issue":"1","key":"592_CR1","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2007.09.019","volume":"53","author":"JP van de Merwe","year":"2008","unstructured":"van de Merwe JP, Nordling J, Bouchelouche P, Bouchelouche K, Cervigni M, Daha LK, et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome\/interstitial cystitis: an ESSIC proposal. Eur Urol. 2008;53(1):60\u20137.","journal-title":"Eur Urol"},{"issue":"S1","key":"592_CR2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/iju.13971","volume":"26","author":"KE Whitmore","year":"2019","unstructured":"Whitmore KE, Fall M, Sengiku A, Tomoe H, Logadottir 0, Kim YH. Hunner lesion versus non-Hunner lesion interstitial cystitis\/bladder pain syndrome. Int J Urol. 2019;26(S1):26\u201334.","journal-title":"Int J Urol"},{"issue":"11","key":"592_CR3","doi-asserted-by":"crossref","first-page":"e0143316","DOI":"10.1371\/journal.pone.0143316","volume":"10","author":"D Maeda","year":"2015","unstructured":"Maeda D, et al. Hunner-type (classic) interstitial cystitis: a distinct inflammatory disorder characterized by pancystitis, with frequent expansion of clonal B-cells and epithelial denudation. PLoS One. 2015;10(11):e0143316.","journal-title":"PLoS One"},{"issue":"0","key":"592_CR4","first-page":"1","volume":"0","author":"M Fall","year":"2020","unstructured":"\u2022 Fall M, et al. Hunner lesion disease differs in diagnosis , treatment and outcome from bladder pain syndrome: an ESSIC working group report. Scand J Urol. 2020;0(0):1\u20138. A recent paper by field specialist inquiring the need to separate BPS from IC.","journal-title":"Scand J Urol"},{"issue":"4S","key":"592_CR5","doi-asserted-by":"crossref","first-page":"9250","DOI":"10.1016\/j.juro.2017.02.928","volume":"197","author":"A Crane","year":"2017","unstructured":"\u2022 Crane A, Lloyd J, Shoskes D. Improving the utility of clinical phenotyping in interstitial cystitis\/painful bladder syndrome: from UPOINT to INPUT. J Urol. 2017;197(4S):9250\u20134. A new phenotyping type proposed to BPS\/IC patients.","journal-title":"J Urol"},{"issue":"3","key":"592_CR6","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1097\/JU.0000000000000250","volume":"202","author":"HH Lai","year":"2019","unstructured":"Lai HH, Thu JHL, Moh FV, Paradis A, Vetter J. Clustering of patients with interstitial cystitis\/bladder pain syndrome and chronic prostatitis\/chronic pelvic pain syndrome. J Urol. 2019;202(3):546\u201351.","journal-title":"J Urol"},{"key":"592_CR7","unstructured":"Engeler SED, Baranowski AP, Berghmans B, Borovicka J, Cottrell AM, Dinis-Oliveira P, et al. A.C. de C Williams Guidelines Associates: L. Pacheco-Figueiredo, B. Parsons, \u2018EAU guidelines on chronic pelvic Pain\u2019. Eur Urol. 2019."},{"issue":"5","key":"592_CR8","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.juro.2015.01.086","volume":"193","author":"PM Hanno","year":"2015","unstructured":"Hanno PM, Erickson D, Moldwin R, Faraday MM. Diagnosis and treatment of interstitial cystitis\/bladder pain syndrome: AUA guideline amendment. J Urol. 2015;193(5):1545\u201353.","journal-title":"J Urol"},{"issue":"7","key":"592_CR9","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1442-2042.2009.02326.x","volume":"16","author":"Y Homma","year":"2009","unstructured":"Homma Y, Ueda T, Tomoe H, Lin ATL, Kuo HC, Lee MH, et al. Clinical guidelines for interstitial cystitis and hypersensitive bladder syndrome: guidelines. Int J Urol. 2009;16(7):597\u2013615.","journal-title":"Int J Urol"},{"issue":"5","key":"592_CR10","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/bju.14399","volume":"122","author":"S Malde","year":"2018","unstructured":"\u2022 Malde S, Palmisani S, Al-Kaisy A, Sahai A. Guideline of guidelines: bladder pain syndrome. BJU Int. 2018;122(5):729\u201343. An interesting paper that compares different guidelines around the world, in terms of BPS\/IC management.","journal-title":"BJU Int"},{"issue":"5","key":"592_CR11","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/S0090-4295(02)01775-2","volume":"60","author":"KJ Propert","year":"2002","unstructured":"Propert KJ, Payne C, Kusek JW, Nyberg LM. Pitfalls in the design of clinical trials for interstitial cystitis. Urology. 2002;60(5):742\u20138.","journal-title":"Urology"},{"issue":"jul21 1","key":"592_CR12","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339(jul21 1):b2535.","journal-title":"BMJ"},{"issue":"4","key":"592_CR13","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.juro.2015.10.178","volume":"195","author":"JC Nickel","year":"2016","unstructured":"\u2022 Nickel JC, et al. Tanezumab reduces pain in women with interstitial cystitis\/bladder pain syndrome and patients with nonurological associated somatic syndromes. J Urol. 2016;195(4):942\u20138. A pooled analysis of 3 RCT evaluating pain reduction in BPS\/IC not only but especially female patients treated with a monoclonal anti-body against NGF.","journal-title":"J Urol"},{"issue":"5","key":"592_CR14","first-page":"S1","volume":"25","author":"B Yurke","year":"2019","unstructured":"Yurke B, Stoler D, Laboratories TB, Hill M. Montelukast trial. Female Pelvic Med Reconstr Surg. 2019;25(5):S1\u2013S25.","journal-title":"Female Pelvic Med Reconstr Surg"},{"key":"592_CR15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.urology.2017.05.016","volume":"107","author":"IM Crescenze","year":"2017","unstructured":"Crescenze IM, Tucky B, Li J, Moore C, Shoskes DA. Efficacy, side effects, and monitoring of oral cyclosporine in interstitial cystitis-bladder pain syndrome. Urology. Sep. 2017;107:49\u201354.","journal-title":"Urology"},{"key":"592_CR16","doi-asserted-by":"crossref","unstructured":"\u2022 Cervigni M, Nasta L, Schievano C, Lampropoulou N, Ostardo E. Micronized palmitoylethanolamide-polydatin reduces the painful symptomatology in patients with interstitial cystitis\/bladder pain syndrome. Biomed Res Int. 2019, 2019. A recent RCT assessing pain reduction in BPS\/IC patients treated with Micronized Palmitoylethanolamide-Polydatin.","DOI":"10.1155\/2019\/9828397"},{"issue":"1","key":"592_CR17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.juro.2013.06.038","volume":"191","author":"PC Bosch","year":"2014","unstructured":"Bosch PC. A randomized, double-blind, placebo controlled trial of adalimumab for interstitial cystitis\/bladder pain syndrome. J Urol. Jan. 2014;191(1):77\u201382.","journal-title":"J Urol"},{"issue":"1","key":"592_CR18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.urology.2014.02.050","volume":"84","author":"H Chen","year":"2014","unstructured":"Chen H, Wang F, Chen W, Ye, Zhou Q, Shao F, et al. Efficacy of daily low-dose sildenafil for treating interstitial cystitis: results of a randomized, double-blind, placebo-controlled trial\u2014treatment of interstitial cystitis\/painful bladder syndrome with low-dose sildenafil. Urology. 2014;84(1):51\u20136.","journal-title":"Urology"},{"issue":"2","key":"592_CR19","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/JU.0000000000000192","volume":"202","author":"JC Nickel","year":"2019","unstructured":"\u2022 Nickel JC, et al. Targeting the SHIP1 pathway fails to show treatment benefit in interstitial cystitis\/bladder pain syndrome: lessons learned from evaluating potentially effective therapies in this enigmatic syndrome. J Urol. 2019;202(2):301\u20138. A phase III trial to treat BPS\/IC with negatives results, failing to show benefit as the phase-II trial.","journal-title":"J Urol"},{"key":"592_CR20","doi-asserted-by":"crossref","unstructured":"Greiman A, Cox L. Pharmacotherapy for interstitial cystitis\/bladder pain syndrome. Curr Bladder Dysfunct Rep. 2019.","DOI":"10.1007\/s11884-019-00540-9"},{"key":"592_CR21","unstructured":"Burkhard ATFC, Bosch JLHR, Cruz F, Lemack GE, Nambiar AK, Thiruchelvam N, et al. EAU guidelines on urinary incontinence. EAU Guidel. 2019;(March):1\u2013100."},{"issue":"3","key":"592_CR22","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.eururo.2004.10.022","volume":"47","author":"LK Daha","year":"2005","unstructured":"Daha LK, Riedl CR, Lazar D, Hohlbrugger G, Pfl\u00fcger H. Do cystometric findings predict the results of intravesical hyaluronic acid in women with interstitial cystitis? Eur Urol. 2005;47(3):393\u20137.","journal-title":"Eur Urol"},{"issue":"2 Part 1","key":"592_CR23","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0022-5347(17)32739-8","volume":"152","author":"D Felsen","year":"1994","unstructured":"Felsen D, et al. Inflammatory mediator profile in urine and bladder wash fluid of patients with interstitial cystitis. J Urol. 1994;152(2 Part 1):355\u201361.","journal-title":"J Urol"},{"issue":"5","key":"592_CR24","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.eururo.2018.07.026","volume":"74","author":"PC Bosch","year":"2018","unstructured":"\u2022 Bosch PC. A randomized, double-blind, placebo-controlled trial of certolizumab pegol in women with refractory interstitial cystitis\/bladder pain syndrome. Eur Urol. 2018;74(5):623\u201330. An RCT with certolizumab pegol, a novel anti-TNFa, assessing pain and urgency improvement in female BPS\/IC patients, with positive results.","journal-title":"Eur Urol"},{"issue":"11","key":"592_CR25","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/ibd.20225","volume":"13","author":"A Nesbitt","year":"2007","unstructured":"Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, Foulkes R, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor \u03b1 agents. Inflamm Bowel Dis. 2007;13(11):1323\u201332.","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"592_CR26","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2165\/00063030-200822050-00005","volume":"22","author":"T Bourne","year":"2008","unstructured":"Bourne T, Fossati G, Nesbitt A. A PEGylated Fab\u2032 fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action. BioDrugs. 2008;22(5):331\u20137.","journal-title":"BioDrugs"},{"issue":"2","key":"592_CR27","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/ncpuro0408","volume":"3","author":"WD Steers","year":"2006","unstructured":"Steers WD, Tuttle JB. Mechanisms of disease: the role of nerve growth factor in the pathophysiology of bladder disorders. Nat Clin Pract Urol. Feb. 2006;3(2):101\u201310.","journal-title":"Nat Clin Pract Urol"},{"issue":"4","key":"592_CR28","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1046\/j.1464-410X.1997.00097.x","volume":"79","author":"EM Lowe","year":"1997","unstructured":"Lowe EM, Anand P, Terenghi G, Williams-Chestnut RE, Sinicropi DV, Osborne JL. Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis. Br J Urol. 1997;79(4):572\u20137.","journal-title":"Br J Urol"},{"issue":"4","key":"592_CR29","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2174\/157015911798376253","volume":"9","author":"B Frias","year":"2011","unstructured":"Frias B, Lopes T, Pinto R, Cruz F, Duarte Cruz C. Neurotrophins in the lower urinary tract: becoming of age. Curr Neuropharmacol. 2011;9(4):553\u20138.","journal-title":"Curr Neuropharmacol"},{"issue":"5","key":"592_CR30","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.urology.2012.07.035","volume":"80","author":"JC Nickel","year":"2012","unstructured":"Nickel JC, Atkinson G, Krieger JN, Mills IW, Pontari M, Shoskes DA, et al. Preliminary assessment of safety and efficacy in proof-of-concept, randomized clinical trial of tanezumab for chronic prostatitis\/chronic pelvic pain syndrome. Urology. 2012;80(5):1105\u201310.","journal-title":"Urology"},{"issue":"5","key":"592_CR31","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1016\/j.juro.2010.12.088","volume":"185","author":"RJ Evans","year":"2011","unstructured":"Evans RJ, Moldwin RM, Cossons N, Darekar A, Mills IW, Scholfield D. Proof of concept trial of tanezumab for the treatment of symptoms associated with interstitial cystitis. J Urol. 2011;185(5):1716\u201321.","journal-title":"J Urol"},{"issue":"1","key":"592_CR32","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12894-016-0193-z","volume":"17","author":"H Wang","year":"2017","unstructured":"Wang H, Russell LJ, Kelly KM, Wang S, Thipphawong J. Fulranumab in patients with interstitial cystitis\/bladder pain syndrome: observations from a randomized, double-blind, placebo-controlled study. BMC Urol. 2017;17(1):2.","journal-title":"BMC Urol"},{"key":"592_CR33","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.joca.2014.10.005","volume":"23","author":"MC Hochberg","year":"2015","unstructured":"Hochberg MC. Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies. Osteoarthr Cartil. Jan. 2015;23:S18\u201321.","journal-title":"Osteoarthr Cartil"},{"issue":"3","key":"592_CR34","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jogc.2016.12.035","volume":"39","author":"F Murina","year":"2017","unstructured":"\u2022 Murina F, Graziottin A, Felice R, Gambini D. Alpha lipoic acid plus omega-3 fatty acids for vestibulodynia associated With painful bladder syndrome. J Obstet Gynaecol Canada. 2017;39(3):131\u20137. An RCT assessing combination therapy associated with amitriptyline, with positive results, with possible amitriptyline dose reduction.","journal-title":"J Obstet Gynaecol Canada"},{"issue":"2","key":"592_CR35","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0304-3959(82)90097-5","volume":"14","author":"I Pilowsky","year":"1982","unstructured":"Pilowsky I, Hallett EC, Bassett DL, Thomas PG, Penhall RK. A controlled study of amitriptyline in the treatment of chronic pain. Pain. 1982;14(2):169\u201379.","journal-title":"Pain"},{"issue":"10","key":"592_CR36","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1080\/14656566.2018.1491968","volume":"19","author":"LL Giusto","year":"2018","unstructured":"Giusto LL, Zahner PM, Shoskes DA. An evaluation of the pharmacotherapy for interstitial cystitis. Expert Opin Pharmacother. 2018;19(10):1097\u2013108.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"592_CR37","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.pain.2010.09.023","volume":"152","author":"FH Lee","year":"2011","unstructured":"Lee FH, Raja SN. Complementary and alternative medicine in chronic pain. Pain. 2011;152(1):28\u201330.","journal-title":"Pain"},{"issue":"6","key":"592_CR38","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1248\/bpb.33.1070","volume":"33","author":"K Nakamoto","year":"2010","unstructured":"Nakamoto K, Nishinaka T, Mankura M, Fujita-Hamabe W, Tokuyama S. Antinociceptive effects of docosahexaenoic acid against various pain stimuli in mice. Biol Pharm Bull. 2010;33(6):1070\u20132.","journal-title":"Biol Pharm Bull"},{"issue":"10","key":"592_CR39","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1111\/j.1743-6109.2012.02915.x","volume":"10","author":"RJ Leo","year":"2013","unstructured":"Leo RJ, Dewani S. A systematic review of the utility of antidepressant pharmacotherapy in the treatment of vulvodynia pain. J Sex Med. 2013;10(10):2497\u2013505.","journal-title":"J Sex Med"},{"issue":"6","key":"592_CR40","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1111\/bph.12039","volume":"168","author":"GR Stenton","year":"2013","unstructured":"Stenton GR, Mackenzie LF, Tam P, Cross JL, Harwig C, Raymond J, et al. Characterization of AQX-1125, a small-molecule SHIP1 activator. Br J Pharmacol. Mar. 2013;168(6):1506\u201318.","journal-title":"Br J Pharmacol"},{"issue":"3","key":"592_CR41","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.juro.2016.03.003","volume":"196","author":"JC Nickel","year":"2016","unstructured":"Nickel JC, Egerdie B, Davis E, Evans R, Mackenzie L, Shrewsbury SB. A phase II study of the efficacy and safety of the novel oral SHIP1 activator AQX-1125 in subjects with moderate to severe interstitial cystitis\/bladder pain syndrome. J Urol. 2016;196(3):747\u201354.","journal-title":"J Urol"},{"issue":"4","key":"592_CR42","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1097\/01.ju.0000159198.83103.01","volume":"173","author":"JC Nickel","year":"2005","unstructured":"Nickel JC, et al. Pentosan polysulfate sodium therapy for men with chronic pelvic pain syndrome: a multicenter, randomized, placebo controlled study. J Urol. Apr. 2005;173(4):1252\u20135.","journal-title":"J Urol"},{"issue":"3","key":"592_CR43","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S0022-5347(17)43242-3","volume":"138","author":"\u00c5 Fritjofsson","year":"1987","unstructured":"Fritjofsson \u00c5, Fall M, Juhlin R, Persson BE, Ruutu M. Treatment of ulcer and nonulcer interstitial cystitis with sodium pentosanpolysulfate: a multicenter trial. J Urol. Sep. 1987;138(3):508\u201312.","journal-title":"J Urol"},{"issue":"6","key":"592_CR44","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/0090-4295(90)80116-5","volume":"35","author":"SG Mulholland","year":"1990","unstructured":"Mulholland SG, Sant GR, Hanno P, Staskin DR, Parsons L. Pentosan polysulfate sodium for therapy of interstitial cystitis. Urology. 1990;35(6):552\u20138.","journal-title":"Urology"},{"issue":"6","key":"592_CR45","doi-asserted-by":"crossref","first-page":"821","DOI":"10.2165\/00003495-200666060-00006","volume":"66","author":"VR Anderson","year":"2006","unstructured":"Anderson VR, Perry CM. Pentosan polysulfate. Drugs. 2006;66(6):821\u201335.","journal-title":"Drugs"},{"issue":"3","key":"592_CR46","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.juro.2014.09.036","volume":"193","author":"JC Nickel","year":"2015","unstructured":"Nickel JC, Herschorn S, Whitmore KE, Forrest JB, Hu P, Friedman AJ, et al. Pentosan polysulfate sodium for treatment of interstitial cystitis\/bladder pain syndrome: insights from a randomized, double-blind, placebo controlled study. J Urol. 2015;193(3):857\u201362.","journal-title":"J Urol"},{"issue":"9","key":"592_CR47","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1080\/03007995.2019.1586401","volume":"35","author":"A van Ophoven","year":"2019","unstructured":"\u2022 van Ophoven A, Vonde K, Koch W, Auerbach G, Maag KP. Efficacy of pentosan polysulfate for the treatment of interstitial cystitis\/bladder pain syndrome: results of a systematic review of randomized controlled trials. Curr Med Res Opin. 2019;35(9):1495\u2013503. Although not directly assessed in this paper, is a recent valuable systematic review over the effect of PPS in BPS\/IC patients.","journal-title":"Curr Med Res Opin"},{"issue":"11","key":"592_CR48","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.ophtha.2018.04.026","volume":"125","author":"WA Pearce","year":"2018","unstructured":"\u2022 Pearce WA, Chen R, Jain N. Pigmentary maculopathy associated with chronic exposure to pentosan polysulfate sodium. Ophthalmology. 2018;125(11):1793\u2013802. A recent paper with a case series of patients developing maculopaty follwing long-term treatment with PPS.","journal-title":"Ophthalmology"},{"issue":"June","key":"592_CR49","first-page":"2001","volume":"57","author":"S Larsen","year":"2001","unstructured":"Larsen S, Hald T, Bouchelouche P. Clinical biomarkers. Urology. 2001;57(June):2001.","journal-title":"Urology"},{"issue":"7","key":"592_CR50","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1046\/j.1464-410x.2001.02135.x","volume":"87","author":"K Bouchelouche","year":"2001","unstructured":"Bouchelouche K, Horn T, Nordling J, Larsen S, Hald T. The action of cysteinyl-leukotrienes on intracellular calcium mobilization in human detrusor myocytes. BJU Int. 2001;87(7):690\u20136.","journal-title":"BJU Int"},{"issue":"7","key":"592_CR51","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1046\/j.1365-2230.2002.01148.x","volume":"27","author":"NJ Reynolds","year":"2002","unstructured":"Reynolds NJ, Al-Daraji WI. Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology. Clin Exp Dermatol. 2002;27(7):555\u201361.","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"592_CR52","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/j.1572-0241.2007.01718.x","volume":"103","author":"MB Sternthal","year":"2008","unstructured":"Sternthal MB, Murphy SJ, George J, Kornbluth A, Lichtiger S, Present DH. Adverse events associated with the use of cyclosporine in patients with inflammatory bowel disease. Am J Gastroenterol. 2008;103(4):937\u201343.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"592_CR53","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3892\/etm.2016.3301","volume":"12","author":"Z Wang","year":"2016","unstructured":"Wang Z, Zhang L. Treatment effect of cyclosporine a in patients with painful bladder syndrome\/interstitial cystitis: a systematic review. Exp Ther Med. 2016;12(1):445\u201350.","journal-title":"Exp Ther Med"},{"issue":"1","key":"592_CR54","doi-asserted-by":"crossref","first-page":"e462","DOI":"10.1016\/S1569-9056(14)60456-5","volume":"13","author":"J Chade","year":"2014","unstructured":"Chade J, Chade D, Lucon AM, Bruschini H, Srougi M. 5-year follow-up of patients with refractory interstitial cystitis treated with cyclosporine A: a prospective single-institution study. Eur Urol Suppl. 2014;13(1):e462.","journal-title":"Eur Urol Suppl"},{"issue":"4","key":"592_CR55","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.juro.2012.06.023","volume":"188","author":"JB Forrest","year":"2012","unstructured":"Forrest JB, Payne CK, Erickson DR. Cyclosporine a for refractory interstitial cystitis\/bladder pain syndrome: experience of 3 tertiary centers. J Urol. 2012;188(4):1186\u201391.","journal-title":"J Urol"},{"issue":"7","key":"592_CR56","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00192-017-3547-5","volume":"29","author":"A Furuta","year":"2018","unstructured":"Furuta A, Yamamoto T, Suzuki Y, Gotoh M, Egawa S, Yoshimura N. Comparison of inflammatory urine markers in patients with interstitial cystitis and overactive bladder. Int Urogynecol J. 2018;29(7):961\u20136.","journal-title":"Int Urogynecol J"},{"issue":"2","key":"592_CR57","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10787-013-0191-7","volume":"22","author":"SD Skaper","year":"2014","unstructured":"Skaper SD, Facci L, Fusco M, della Valle MF, Zusso M, Costa B, et al. Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology. 2014;22(2):79\u201394.","journal-title":"Inflammopharmacology"}],"container-title":["Current Bladder Dysfunction Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11884-020-00592-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11884-020-00592-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11884-020-00592-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T23:19:16Z","timestamp":1624749556000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11884-020-00592-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,27]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["592"],"URL":"https:\/\/doi.org\/10.1007\/s11884-020-00592-2","relation":{},"ISSN":["1931-7212","1931-7220"],"issn-type":[{"value":"1931-7212","type":"print"},{"value":"1931-7220","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,27]]},"assertion":[{"value":"27 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}